Plasma Patents (Class 424/530)
-
Patent number: 7871630Abstract: The invention relates to compositions, kits, and methods for alleviating cancer (i.e., a tumor) in a human patient. The therapeutic modality effected by the invention involves inducing a type 1 inflammatory response in the tumor tissue, whereby the tumor tissue is diminished or destroyed and the patient develops immune memory that inhibits or prevents recurrence of the tumor.Type: GrantFiled: June 9, 2005Date of Patent: January 18, 2011Assignee: BioTHER CorporationInventor: Eugene Roussel
-
Publication number: 20110008459Abstract: A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0.Type: ApplicationFiled: September 17, 2010Publication date: January 13, 2011Inventors: Wolfgang Marguerre, Tor-Einar Svae
-
Publication number: 20110008458Abstract: A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to promote healing of the wound. The released growth factors are applied topically to the area of a surface wound to effect healing. The released growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by conventional lyophilization. Then at a later date, the freeze dried product is reconstituted by normal saline for treatment of a patient's wound or for use in a surgical procedure.Type: ApplicationFiled: July 9, 2009Publication date: January 13, 2011Inventors: James Gandy, Robert J. Brandt, Ryan N. Brandt, Clark Galen, Joseph Greco, John Kiwczak
-
Patent number: 7867519Abstract: A method for modifying the properties of a fibrin matrix relative to growth and ingrowth of cells, wherein for forming the fibrin matrix a fibrinogen is used consisting of a selected fibrinogen variant or a fibrinogen enriched or depleted in a selected fibrinogen variant. In particular, the use of high-molecular weight (HMW) fibrinogen leads to a fibrin having accelerated angiogenesis properties, while the use of low-molecular weight (LMW and/or LMW?) fibrinogen leads to fibrin having decelerated angiogenesis properties. The use of HMW fibrinogen when setting up angiogenesis tests results in that the tests require less time. Fibrin sealants on the basis of HMW fibrinogen can be used for burns, to promote wound healing or to inhibit scar tissue. Fibrin sealants on the basis of LMW or LMW? fibrinogen are useful to inhibit adhesions and tumor growth, for instance after surgical operations.Type: GrantFiled: April 7, 2003Date of Patent: January 11, 2011Assignee: Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek TNOInventors: Monica Petronella Maria de Maat, Pieter Koolwijk
-
Patent number: 7858087Abstract: The present invention is directed to a composition and method for enhancing the complement-mediated cytotoxicity of therapeutic antibodies for their target cells (i.e. those cells displaying the target epitope). More particularly the present invention enhances the efficacy of such therapies by providing a supplemental source of complement.Type: GrantFiled: July 25, 2007Date of Patent: December 28, 2010Assignee: University of Virginia Patent FoundationInventors: Ronald P. Taylor, Margaret A. Lindorfer, Michael D. Solga, Adam Kennedy
-
Publication number: 20100323029Abstract: Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood.Type: ApplicationFiled: June 16, 2010Publication date: December 23, 2010Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Mauro Tiso
-
Publication number: 20100316727Abstract: Methods for therapeutic treatment of inflammatory conditions in a mammalian patient provide clinical benefits including reduction of inflammation, vasorelaxation, reduction in edema and increased blood flow, the methods generally comprising extracorporeal treatment of blood, blood fractionate, or other biological fluid to expose such fluids to a precise, measured amount of ozone to produce a blood or biological fluid having a quantified absorbed dose of ozone, and reinfusing the treated biological fluid to the patient to provide therapeutic effects beneficial in the treatment of inflammatory disorders and related symptoms or conditions.Type: ApplicationFiled: June 21, 2010Publication date: December 16, 2010Inventors: Joseph S. Latino, Steven A. Keyser
-
Publication number: 20100310524Abstract: The invention relates to the use of viral inactivated-plasma cryoprecipitate concentrate (VIPCC) comprising a suitable fibronectin/fibrinogen ratio for treating a spine disease, disorder or condition such as intervertebral disc degeneration.Type: ApplicationFiled: August 29, 2008Publication date: December 9, 2010Inventors: Edna Bechor, Liliana Bar, Israel Nur
-
Patent number: 7838039Abstract: Provided are methods of applying biological compositions, that is, autologous bioadhesive sealant compositions containing one or more biological agents, to an individual, wherein all the blood components used in preparing the composition are derived from the patient who is to receive the biological composition. In one embodiment, the method comprises obtaining a whole blood sample from an individual; forming an inactive platelet rich plasma from the whole blood sample; mixing a biological agent into the inactive platelet rich plasma; obtaining thrombin from the whole blood sample; mixing the thrombin into the inactive platelet rich plasma to form a biological composition; and applying the biological composition to the individual.Type: GrantFiled: January 27, 2005Date of Patent: November 23, 2010Assignee: Arteriocyte Medical Systems, Inc.Inventors: Robert F. Baugh, Lisa M. Lim, Julie S. Johnston, John G. Rivera
-
Publication number: 20100285146Abstract: A method is disclosed for treating systemic lupus erythematosus in a mammalian subject, comprising administering to said subject an effective dose of at least one laminin peptide, or an analog or a derivative thereof. In one exemplary embodiment, the laminin peptide is selected from the group consisting of R38 (SEQ. ID. NO. 1), and claimed R38 analogs and derivatives thereof including 5200 (SEQ. ID. NO. 10), 5104 (SEQ. ID. NO. 15), 5105 (SEQ. ID. NO. 16), 5106 (SEQ. ID. NO. 17), 5107 (SEQ. ID. NO. 18), 5108 (SEQ. ID. NO. 19), 5109 (SEQ. ID. NO. 20), 5110 (SEQ. ID. NO. 21). The laminin peptides of the present invention may be prepared by known chemical synthetic methods or by biotechnological methods. The invention also provides assays useful for the diagnosis of and following pathological activity course of systemic lupus erythematosus in patients suffering therefrom.Type: ApplicationFiled: May 22, 2008Publication date: November 11, 2010Inventor: Yaakov Naparstek
-
Publication number: 20100266707Abstract: A method of treating cachexia is disclosed involving the removal or inactivation of macrophage inhibitory cytokine-1 (MIC-1) present in the blood, plasma or serum of a cachexia subject. In one embodiment, the method comprises the steps of providing a suitable substrate for binding MIC-1 (e.g. a substrate provided with a MIC-1 binding molecule), treating blood, plasma or serum removed from a subject by contacting the blood, plasma or serum ex vivo with the substrate such that MIC-1 present in the blood, plasma or serum is bound to the substrate, separating the treated blood, plasma or serum from the substrate, and thereafter returning the treated blood, plasma or serum to the subject. Also disclosed, is a method of diagnosing or prognosing cachexia in a subject, said method comprising determining the amount of MIC-1 present in the subject.Type: ApplicationFiled: October 9, 2008Publication date: October 21, 2010Inventor: Samuel Norbert Breit
-
Publication number: 20100260815Abstract: The present invention provides devices and methods for concentrating a fluid and for treating a patient with the concentrated fluid. The concentrator apparatus includes a main housing (12) defining a separation chamber (14), a filter housing (48) containing a filter (46) comprising a filter element, a piping (44) for moving concentrated fluid from the separation chamber to the filter, and ports (32) for pressurizing the concentrated fluid past the filter element of the filter. The present invention also provides a variety of uses of concentrated body fluids, including autologous concentrated body fluid. The concentrated fluids can be used for example in surgical applications, including graft applications such as allograft, xenograft and autograft applications.Type: ApplicationFiled: June 20, 2008Publication date: October 14, 2010Applicant: Circle Biologics , LLCInventors: Matthew R. Kyle, Thomas Coull
-
Patent number: 7811607Abstract: The present relates to an autologous bioadhesive sealant composition or fibrin glue prepared by a two-phase method, wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. A platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. In one embodiment, the platelet rich plasma is divided into two portions. In phase one, a compound that reverses the effect of the anticoagulant is added to the first portion and a clot is allowed to form. The clot is then triturated, and the resulting serum containing autologous thrombin is collected. In phase two, the serum obtained from phase one is mixed with the second portion of the platelet rich plasma to form the bioadhesive sealant of the present invention.Type: GrantFiled: December 3, 2004Date of Patent: October 12, 2010Assignee: Arteriocyte Medical Systems, Inc.Inventors: Robert F. Baugh, Lisa M. Lim, Julie S. Johnston, John G. Rivera
-
Publication number: 20100233282Abstract: A method of delivering a bioactive composition to the right side of the heart is described. The method can be used to treat cardiac dysfunction such as myocardial infarction, arrhythmias or congestive heart failure. A dual lumen catheter is described for delivering the bioactive substance by inserting a first cannula of a dual lumen catheter into a vein to access the right ventricle. The first cannula has a first balloon which is blown up proximal to the tricuspid valve. A second cannula is then introduced which accesses the right side of the heart and coronary sinus. The bioactive substance is then delivered to the right side of the heart. The bioactive substance may include platelets and/or white blood cells at concentrations higher than what is normally found in whole blood.Type: ApplicationFiled: March 12, 2010Publication date: September 16, 2010Inventor: Allan Mishra
-
Patent number: 7794720Abstract: The present invention relates to isolated canine animal plasma, a method for isolating canine animal plasma, plasma obtained form an immunised or hyperimmunised canine animal and treating a canine animal with the isolated canine animal plasma. The method includes the step of selecting a canine animal having a blood group compatible with a recipient canine animal having an unmatched blood group, namely, selecting a canine animal for a blood group that does not cause plasma transfusion reaction and/or haemolysis. In one form, the method includes the step of immunising or hyperimmunising a canine animal plasma donor with one or more antigens of a canine animal pathogen. The pathogen is preferably a bacteria or virus.Type: GrantFiled: April 29, 2004Date of Patent: September 14, 2010Assignee: Plasma Ventures Pty LtdInventor: Ross Phillip Wilson
-
Publication number: 20100209518Abstract: A method for forming micro-particles is provided. The method includes the steps of: —providing a first solution which includes at least an anion; —providing a second solution which includes at least a cation; —mixing the first solution with the second solution in presence of at least a first compound for forming porous templates, wherein the porous templates are formed by precipitation of a salt which includes the anion and the cation and wherein the first compound is at least partially incorporated in the porous templates; and—at least partially cross-linking the first compound in the porous templates.Type: ApplicationFiled: July 14, 2008Publication date: August 19, 2010Inventor: Radostina GEORGIEVA
-
Publication number: 20100196497Abstract: This invention is a method of treating a patient's injured tissue by applying platelet-rich plasma and laser energy to the injured tissue. The applied energy is low-level, and the patient feels no sensation of the low-level laser energy being applied. The laser energy can be applied before, after, or during the platelet-rich plasma application, or any combination thereof. Additional laser therapy may be applied over the entire extremity containing the injury, any non-injured adjacent tissue, as well as to the patient's entire body for stimulation of other body systems. Additionally, laser energy can be applied to the platelet-rich plasma before the platelet-rich plasma is applied to the patient.Type: ApplicationFiled: February 2, 2010Publication date: August 5, 2010Applicant: THERAPY PRODUCTS, INC.Inventors: Susan M.L. LIM, Steven C. SHANKS, Ryan MALONEY
-
Publication number: 20100196461Abstract: A method for treating conditions related to lack of blood supply with a resuscitation fluid is disclosed. The resuscitation fluid contains a lipophilic component and a polar liquid carrier. The lipophilic component forms an emulsion with the polar liquid carrier. The resuscitation fluid can be used to increase the blood pressure and to carry oxygen and other lipophilic gases to tissues. The resuscitation fluid can also be used for preserving the biological integrity of donor organs for transplantation.Type: ApplicationFiled: January 29, 2010Publication date: August 5, 2010Inventor: Cuthbert O. Simpkins
-
Publication number: 20100189802Abstract: A method comprising preparing a vascular hyperpermeability treatment composition comprising an apoptosis regulating protein, a antioxidant, a mitochondrial modulator, a biological effector molecule, or combinations thereof in a form deliverable to a mammal; whereby an effective amount of the composition raises the threshold for apoptosis and/or prevents or lessens the occurrence of vascular hyperpermeability. A method comprising preventing hyperpermeability associated with hemorrhagic shock via preparing a composition in a form deliverable to a mammal, the composition comprising an apoptosis regulating protein, a antioxidant, a mitochondrial modulator, a biological effector molecule, or combinations thereof; and raising the threshold for apoptosis in a mammal's endothelial cells by administering an effective amount of said antioxidant; whereby said raising the threshold for apoptosis prevents said hyperpermeability.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Applicant: Scott and White Memorial Hospital and Scott, Sherwood, and Brindley FoundationInventors: Ed W. Childs, W. Roy Smythe
-
Publication number: 20100183561Abstract: Novel uses of Platelet Rich Plasma (PRP) for infection prevention, bone repair and transmyocardial vascularization is disclosed. The present disclosure is directed to methods for preparing concentrated mesenchymal or haematopoietic stem cells, and autologous platelet-rich plasma (PRP) from the blood utilizing the Magallen® System. The stem cells and/or PRP may be combined with secondary biological agents such as antibiotics, fibrinogen and thrombin, and appropriately used in variety of medical conditions, such as, cardiovascular, thoracic, transplantation, head and neck, oral, gastrointestinal, orthopedic, neurosurgical, and plastic surgery.Type: ApplicationFiled: July 7, 2009Publication date: July 22, 2010Applicant: ARTERIOCYTE MEDICAL SYSTEMSInventors: Ramasamy Sakthivel, Donald J. Brown, Yukang Zhao, Adam Sorkin, Vincent Pompili, Kevin Mcintosh
-
Publication number: 20100159023Abstract: Process for the stabilization of blood plasma components in a lyophilizate, wherein in a freeze-drying process, said blood plasma components were in a solution containing at least two different pH-lowering substances causing a predetermined pH value range to be adjusted in the solution formed upon reconstitution.Type: ApplicationFiled: February 15, 2008Publication date: June 24, 2010Inventors: Kim Bjornstrup, Martin Kern, Andrea Heger, Gerhard Gruber, Hans Sachse, Raimund Schuetz, Juergen Roemisch, Tor-Einar Svae
-
Publication number: 20100150882Abstract: Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, A? phagocytic activity was increased and soluble and insoluble A? protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of A?1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.Type: ApplicationFiled: February 16, 2010Publication date: June 17, 2010Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Jun Tan, Paul Sanberg
-
Publication number: 20100112081Abstract: Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically. In some embodiments, the PRP composition may be coated on one or more medical devices. The PRP composition may be delivered to an identified portion of the electrical conduction system of the heart affected and/or causing the arrhythmia to occur.Type: ApplicationFiled: October 7, 2009Publication date: May 6, 2010Applicant: BioParadox, LLCInventors: Allan Kumar Mishra, Todd Jeffrey Brinton
-
Patent number: 7700132Abstract: An endogenous mammalian material has been found which has the biological effect of causing a reduction in the mass of mammalian organs including the heart and prostate. The material has physico-chemical properties such that it appears as a compound of molecular weight between 10 and 20 kD when subjected to a purification process using membrane filtration followed by gel filtration. This material has therapeutic uses including the treatment of organ or tissue hypertrophy and hyperplasia.Type: GrantFiled: June 30, 2005Date of Patent: April 20, 2010Assignee: Endocrine Pharmaceuticals LimitedInventor: John Ernest Hart
-
Patent number: 7662411Abstract: The present invention relates to a process of disinfecting biological materials. In particular, a novel process is provided for removing detergent and/or solvent added to biological materials for the inactivation of viral contaminants. Safe, efficient, and economical methods for removing virucidal agents such as solvent-detergent from virus-inactivated pooled plasma by hydrophobic interaction chromatography are provided. Methods for clearing solvent-detergent from virus-inactivated biological materials in a single step are also provided.Type: GrantFiled: June 29, 2005Date of Patent: February 16, 2010Assignee: Reliance Life Sciences Pvt. Ltd.Inventors: Chandra Viswanathan, Mosuvan Kuppusamy, Manjunath Kamath, Vilas Baikar, Arati Tanavade, Narahari R. Prasad, Ritesh Dhundi
-
Patent number: 7645860Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: August 1, 2008Date of Patent: January 12, 2010Assignees: Baxter Healthcare S.A., Baxter International Inc.Inventors: Peter Turecek, Juergen Siekmann
-
Patent number: 7641918Abstract: A method for specifically removing or isolating plasmin(ogen) or plasmin in presence of fibrinogen from a mixture containing plasmin(ogen) or plasmin by contacting the mixture with a rigid amino acid wherein the amino group of the amino acid and the carboxylic group of the amino acid are about 6-8 Angstroms, preferably about 7 Angstroms apart and the rigid amino acid is covalently bound to the support via the amino group of the amino acid.Type: GrantFiled: October 17, 2006Date of Patent: January 5, 2010Assignee: Omrix Biopharmaceuticals Inc.Inventors: Israel Nur, Liliana Bar, Malkit Azachi
-
Publication number: 20090317483Abstract: The invention relates to new biocomponent bioadhesive formulations, with a synthetic part and an autologous biological part of blood origin comprising plasma rich in platelets and in growth factors, and its use of same in biomedicine, preferably in opththalmic surgery.Type: ApplicationFiled: October 25, 2005Publication date: December 24, 2009Applicant: INSTITUTO OFTALMOLOGICO DE ALICANTE, S.L.Inventors: Jorge Luciano Alió Sanz, Marta Abad Collado, Alejandra Sanchez Torregrosa
-
Publication number: 20090297485Abstract: Treatment methods are disclosed for psychiatric and neurodegenerative disorders by treatment of the patient with platelet-rich plasma (PRP). PRP is administered to areas of the brain that have been identified as associated with the psychiatric or neurodegenerative disorder to replenish the dysfunctional tissue.Type: ApplicationFiled: May 28, 2009Publication date: December 3, 2009Inventor: Allan Mishra
-
Method of removing carbon monoxide from an oxygen carrier and apparatus for removing carbon monoxide
Patent number: 7601201Abstract: A method of removing carbon monoxide from an oxygen carrier including setting a carbon monoxide bonded oxygen carrier solution across a separation membrane from an oxygen-dissolved solution; and exposing the setting part to the light and a method of removing carbon monoxide from an oxygen carrier including setting a carbon monoxide oxygen carrier solution across a hollow fiber separation membrane from an oxygen-dissolved solution; and exposing the setting part to light.Type: GrantFiled: April 13, 2006Date of Patent: October 13, 2009Assignee: Nipro CorporationInventors: Ippei Fukutomi, Toshiya Kai, Naohisa Katayama, Takeshi Nizuka, Yoshinori Kida -
Patent number: 7592134Abstract: The present invention relates to a plasma product or a serum product with an extremely low risk of viral contamination and a method for producing the same. Before treating plasma or serum to be used as a raw material for producing a plasma product or a serum product using a virus removal membrane, leucocytes contaminating the blood are removed. Thus, a plasma product or a serum product with an extremely low risk of viral contamination can be efficiently produced while preventing clogging. Since clogging scarcely arises, it is possible to carry out efficient filtration without applying an elevated pressure as the filtration proceeds.Type: GrantFiled: October 16, 2003Date of Patent: September 22, 2009Assignee: Asahi Kasei Medical Co., Ltd.Inventors: Sakae Sato, Tetsuo Sato, Thierry Burnouf, Miryana Radosevich, Hadi Alphonse Goubran
-
Publication number: 20090220469Abstract: The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with glaucoma, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said peptides—especially in apheresis—for the treatment of glaucoma.Type: ApplicationFiled: March 9, 2007Publication date: September 3, 2009Applicants: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH, FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBER GInventors: Gerd Wallukat, Rudolf Kunze, Martin Herrmann, Reinhard Voll, Anselm Junemann, Ursula Schloetzer
-
Patent number: 7572465Abstract: A material having the ability to reduce organ mass has been isolated by collecting ovarian venous blood from a female mammal; preparing ovarian venous plasma from the blood; and at least partially purifying said material from the plasma. This material has therapeutic and other uses, e.g. in the treatment of organ or tissue hypertrophy.Type: GrantFiled: December 1, 1999Date of Patent: August 11, 2009Assignee: Endocrine Pharmaceuticals LimitedInventor: John Ernest Hart
-
Publication number: 20090196938Abstract: The present invention relates to a method for treating the risk of increased C-reactive protein (CRP) levels by conducting extracorporeal perfusion of blood plasma from patients with risk for cardiovascular diseases or immune dysfunctions, such as autoimmune diseases, through a device, such as a column, which contains absorbent matrix material including lipids, peptides, polypeptides, phosphocholine (PC) or PC derivatives so as to remove C-reactive protein. Moreover, the present invention relates to the use of compounds which have the characteristic to bind CRP at least temporarily, for removing CRP from biological fluids of a patient for prophylaxis and/or treatment of autoimmune diseases, cardiovascular diseases, such as infarction, stroke, diabetes, rheuma and renal failure.Type: ApplicationFiled: December 22, 2006Publication date: August 6, 2009Inventor: Birgit Vogt
-
Publication number: 20090136587Abstract: The present invention relates to a pharmaceutical composition for the treatment of nerve damage, and more particularly to a pharmaceutical composition for the treatment of nerve damage, which contains blood plasma or serum as an active ingredient. The inventive composition regenerates nerve cells after spinal nerve damage and provides complete structural continuity in the spinal nerve lesion sites. Thus, the composition is useful for the treatment of nerve damage.Type: ApplicationFiled: August 8, 2006Publication date: May 28, 2009Applicant: MEDIGENES CO., LTDInventors: Won Min Yoo, Nae Choon Yoo, Ki Chang Keum, Sang Yup Lee, Gene Lee
-
Publication number: 20090092678Abstract: A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0.Type: ApplicationFiled: August 8, 2008Publication date: April 9, 2009Inventors: Wolfgang Marguerre, Tor-Einar Svae
-
Publication number: 20090092679Abstract: A particle/cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted.Type: ApplicationFiled: November 5, 2008Publication date: April 9, 2009Inventor: Allan Mishra
-
Patent number: 7510732Abstract: The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of producing the composition for treating a subject afflicted with inflammation and/or pain.Type: GrantFiled: February 16, 2005Date of Patent: March 31, 2009Assignee: Cambridge Scientific Pty LtdInventors: Jeffrey D. Edwards, John Palermo
-
Publication number: 20090060975Abstract: Methods and systems for delivering biological products such as bone marrow aspirate (BMA) to different surgical sites during surgery (for example, arthroscopic surgery). The biological product is encapsulated or contained within a containment system comprising a carrier such as collagen carrier. The containment system may be formed of water soluble polymers, either natural, synthetic or semisynthetic, provided into films that may be made or molded into various shapes and sizes, and that may be manipulated to confer specific properties (such as solubility or degradation rates according to a specific environment, for example) of such films. The water soluble films may be processed into capsules, packets or other containers.Type: ApplicationFiled: August 26, 2008Publication date: March 5, 2009Inventors: J. Maxwell Teets, Christopher Bare, Tara L. Schaneville
-
Publication number: 20090060974Abstract: Methods of arthroscopic resurfacing of anatomical tissue utilizing a biological component strengthened with glue or similar material. The biological component is selected from the group consisting of blood, blood components, PRP, bone marrow aspirate (BMA) and autologous conditioned plasma (ACP). The biological component/glue composition may be inserted (by injection and/or by employing a biologic resurfacing mold, for example) into, or in the vicinity of, the anatomical tissue. Upon insertion within, or contact with, the anatomical tissue, the biological component/glue composition is designed to coagulate and solidify (or partially solidify) within minutes, to advance healing or tissue growth of the anatomical tissue. The biological component/glue composition may optionally comprise components such as growth factors, antiseptic chemicals and/or antibiotics and/or electrolytes, or hormones or site-specific hybrid proteins, among others.Type: ApplicationFiled: August 26, 2008Publication date: March 5, 2009Inventors: Reinhold Schmieding, Gerlinde Michel, Stephane Naudin, Hans Linden
-
Publication number: 20090035382Abstract: Method for the treatment of articular diseases or articular pain, or for the treatment of skin, which comprises the infiltration or the application of a compound that comprises at least one blood-derived substance, which is preferably a blood plasma in general, and in particular a platelet-rich plasma (PRP), and preferably a plasma rich in growth factors (PRGF), and/or a supernatant of any of the aforementioned plasmas. The inventive method enables the significant relief and even regeneration of the treated areas. Optionally, the blood-derived substance may be mixed with hyaluronic acid (HA) and/or an HA-derived compound, thereby achieving even more beneficial effects.Type: ApplicationFiled: August 4, 2008Publication date: February 5, 2009Applicant: Biotechnology Institute, I MASD, S.L.Inventors: Eduardo ANITUA ALDECOA, Mikel Sanchez Alvarez
-
Patent number: 7482162Abstract: We disclose methods for measuring vitamin D metabolite in plasma or serum samples. The methods comprise a step of adding to the plasma or serum samples a non-competitive displacement agent comprising 8-anilino-1-naphthalenesulfonic acid ammonium salt, 3-(acetonylbenzyl)-4-hydroxycoumarin and a water miscible solvent. The non-competitive displacement agent separates vitamin D metabolite from binding proteins in the sample, such that the displaced vitamin D metabolite is available for capture and detection in subsequent binding assays. Thus, our invention finds use in methods of separating and detecting vitamin D metabolites otherwise tightly bound to plasma or serum binding proteins.Type: GrantFiled: December 6, 2001Date of Patent: January 27, 2009Assignee: Immunodiagnostic Systems Ltd.Inventors: David Laurie, Alexander Kirkley Barnes, Michael James Gardner
-
Publication number: 20080305178Abstract: A blood substitute, of an extracellular haemoglobin having a molecular weight of approximately 3 to approximately 4 million daltons, comp sing chains of polymerised globins, containing free cysteines capable of binding to NO and/or SNO groups, and having a P50 of approximately 6 to approximately 7 mm Hg, and methods using the blood substitute.Type: ApplicationFiled: April 28, 2008Publication date: December 11, 2008Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Franck ZAL, Andre TOULMOND, Francois LALLIER
-
Publication number: 20080299212Abstract: The present invention relates to a pharmaceutical agent for treating Avellino corneal dystrophy, and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy comprising pharmaceutically effective amount of blood plasma or serum as an active ingredient. The pharmaceutical composition of the present invention has an effect of improving symptoms by dissolving away hyaline granules in the cornea of a patient with severe Avellino corneal dystrophy due to LASIK surgery.Type: ApplicationFiled: February 24, 2006Publication date: December 4, 2008Applicant: MEDIGENES CO., LTDInventors: Eung Kweon Kim, Nae-Choon Yoo, Won-Min Yoo
-
Publication number: 20080292597Abstract: A neurological disease is treated by administering to a patient a therapeutically effective amount of a composition including human umbilical cord stem cells. The composition may include growth factors mixed with the stem cells immediately prior to being administered. A specific pre and post transplantation protocol provides optimal methods for obtaining favorable clinical results.Type: ApplicationFiled: July 28, 2005Publication date: November 27, 2008Inventor: David A Steenblock
-
Publication number: 20080286379Abstract: Method and means for obtaining thrombocyte-rich plasma (platelet-rich plasma, PRP) from whole blood which specifically has a high content of specifically activated thrombocytes and which is particularly easy to coagulate.Type: ApplicationFiled: July 29, 2005Publication date: November 20, 2008Inventors: Peter Wehling, Julio Reinecke
-
Publication number: 20080267902Abstract: The present invention provides a non-liquid biomaterial that may be used as a surgical sealant, a suture support, a blood flow controller, an adhesion reducing agent, an adhesion preventing agent, a tissue support, a tissue filler, a wound dressing or a combination thereof. The non-liquid biomaterial may comprise a blood derived material such as plasma, platelet poor plasma, platelet rich plasma or a material derived from blood containing tissue aspirate, such as bone marrow aspirate, a protein binding agent and a polymerizing agent. Methods for making and using the non-liquid biomaterial are also provided.Type: ApplicationFiled: April 27, 2007Publication date: October 30, 2008Inventors: Hillary Enyart, Jacy Hoeppner, Mike Leach, Shon Steger, Sona Sundaramurthy
-
Patent number: 7442308Abstract: A process for removing viruses in fibrinogen solutions and fibrinogen obtained thereof wherein the process starts with an adjusted purified fibrinogen solution, the adjusted purified solution is frozen and then thawed at a temperature between 5 and 20° C., the undissolved materials associated with the fibrinogen are subsequently separated, the temperature is adjusted and the resultant solution is finally subjected to nanofiltration using filters having a pore size smaller than 35 nm.Type: GrantFiled: February 25, 2004Date of Patent: October 28, 2008Assignee: Grifols, S.A.Inventors: Pere Ristol Debart, Jesus Fernandez Rodriguez
-
Publication number: 20080254093Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat injured cardiac tissue is described.Type: ApplicationFiled: June 17, 2008Publication date: October 16, 2008Applicant: Bioparadox, LLCInventor: Allan Mishra
-
Publication number: 20080248082Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat injured cardiac tissue is disclosed.Type: ApplicationFiled: June 17, 2008Publication date: October 9, 2008Applicant: Bioparadox, LLCInventor: Allan Mishra